Accessibility Menu
Adagio Medical logo

Adagio Medical(NASDAQ) ADGM

Current Price$0.49
Market Cap$10.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 YearN/A
1 Year-72%
1 Month-32%
Adagio Medical last closing stock price
MetricPriceDate
Last closeUSD 0.472026-07-22
Adagio Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.25%USD 0.552026-07-15
1 month-31.61%USD 0.682026-06-22
3 month-69.07%USD 1.512026-04-23
Year to date-55.1%USD 1.042025-12-31
1 year-72.37%USD 1.692025-07-22
Since inception-95.8%USD 11.132021-02-26

Adagio Medical Financials at a Glance

Market Cap

$10.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.37M

EPS (TTM)

-$1.49

P/E Ratio

-0.31

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$0.49

Volume

37,898.282

Open

$0.49

Previous Close

$0.47

Daily Range

$0.47 - $0.54

52-Week Range

$0.44 - $2.58

Estimated Earnings Date

Aug 12, 2026

ADGM News

Foolcom-Featured.png

Adagio Medical Posts Narrower Q2 Loss

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adagio Medical

Adagio Medical creates devices that help treat irregular heart rhythms. Its products are used by doctors to restore normal heartbeats. These tools aim to improve patient outcomes in hospitals and clinics.

Gadgets That Keep Hearts in Rhythm

  • iCLAS atrial cryoablation system: Treats irregular upper heart rhythms using ultra-cold energy; targets hospitals and cardiologists.
  • vCLAS ventricular cryoablation system: Designed for dangerous lower heart rhythm disorders; received special FDA status in 2025.
  • Cryopulse pulsed-field cryoablation catheter: Uses electric pulses and cold to treat persistent heart rhythm problems.
  • Accessories and consoles: Support main catheters for use in medical procedures.

Growth Spurts and Strategic Moves

  • 2024: Completed business combination and public listing on NASDAQ.
  • 2024: Entered U.S. market with pivotal clinical trial for vCLAS system.
  • 2025: vCLAS system received FDA Breakthrough Device designation in April.
  • 2025: Prioritized U.S. clinical trials and paused European sales to focus resources.

Why Adagio Is a Bit Different

Adagio focuses on ultra-low temperature ablation, a method to freeze heart tissue and stop faulty signals. Its dual-therapy platform combines cold and electric pulses, aiming to address gaps left by older technologies. The company emphasizes clinical trials and regulatory progress to support its products.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Net loss was $3.95 million in Q2 2025, improved 31% from Q2 2024.
  • Cash and equivalents were $8.2 million as of June 30, 2025.
  • Operating expenses fell 32% year-over-year in Q2 2025.
  • All prior revenue came from Europe; U.S. sales not yet started.

Bottom Line

Adagio has shifted from European sales to focus on U.S. clinical trials and regulatory milestones. The company’s evolution centers on innovation in heart rhythm treatment and adapting to changing market needs.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

41

CEO

Todd Usen, MBA

Website

adagiomedical.com

Headquarters

Laguna Hills, CA 92653, US

ADGM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-382.50%

Return on Capital

-64.08%

Return on Assets

-61.99%

Earnings Yield

-3.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.21M

Volume

37.90K

Avg. Volume

104.77K

Financials (TTM)

Gross Profit

-$431.00K

Operating Income

-$19.61M

EBITDA

-$20.44M

Operating Cash Flow

-$15.93M

Capital Expenditure

$333.00K

Free Cash Flow

-$15.60M

Cash & ST Invst.

$12.91M

Total Debt

$24.09M

Adagio Medical Performance Analysis

Adagio Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 189,000N/A
20232023-12-31USD 0N/A
20242024-12-31USD 602,000N/A
20252025-12-31USD 0N/A
Adagio Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Adagio Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -31.509110.0%
20232023-12-31USD -0.22-99.3%
20242024-12-31USD -4.942170.1%
20252025-12-31USD -1.51-69.4%
Adagio Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3030.0%
Q32025-09-30-88.6%
Q42025-12-3175.8%
Q12026-03-31-93.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$10.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$252.98K

N/A

Employees

41

N/A

Net Income

-$7.00M

+9.3%

EBITDA

-$6.01M

+11.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.91M

-0.4%

Total Debt

$24.09M

+29.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$1.60M

-30.6%

Long Term Debt

$23.86M

+30.3%

Short Term Debt

$225.00K

-14.4%

Return on Assets

-61.99%

N/A

Return on Invested Capital

-63.79%

N/A

Free Cash Flow

-$4.13M

+45.3%

Operating Cash Flow

-$4.13M

+42.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COCHEnvoy Medical, Inc.
$0.68-2.31%
CTXRCitius Pharmaceuticals, Inc.
$0.53-5.41%
IRIXIRIDEX Corporation
$0.92+0.97%
CODXCo-Diagnostics, Inc.
$2.21-3.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.88-0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$66.15-0.06%
QSQuantumScape
$5.17-0.12%
CLFCleveland-Cliffs
$11.20+0.18%

Questions About ADGM

What is the current price of Adagio Medical?

Adagio Medical is trading at $0.50 per share.

What is the 52-week range for Adagio Medical?

Over the past 52 weeks, Adagio Medical has traded between $0.44 and $2.58.

How much debt does Adagio Medical have?

As of the most recent reporting period, Adagio Medical reported total debt of $24.09M.

How much cash does Adagio Medical have on hand?

Adagio Medical reported $12.91M in cash and cash equivalents in its most recent financial results.

What is Adagio Medical’s dividend yield?

Adagio Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services